## 3 Results
### Overall Survival  
The median OS from the time of MM diagnosis was not reached (NR) in the 1L and 2L groups (median follow-up of 430.5 and 813.0 days, respectively) and was 70.2 months (95% CI: 48.8, NR) in the \(\geq\)3L group (median follow-up of 996.0 days; Figure 1). At 36 months, the OS rate was 0.862% in the 1L group, 0.792% in the 2L group, and 0.736% in the \(\geq\)3L group. A trend toward longer OS was observed in the 1L versus 2L group (as indicated by the reciprocal (inverse) HR of 0.658; 95% CI: 0.278, 1.563). When assessed from the first DRd administration, median OS was NR in the 1L and 2L groups (median follow-up of 390.0 and 551.0 days, respectively) and was 36.6 (95% CI: 23.5, NR) months in the \(\geq\)3L group (median follow-up 448.0 days; Figure A4).  
\begin{table}
\begin{tabular}{c c c c} \hline \hline
**Parameter** & **1L DRd** & **2L DRd** & \(\geq\)**3L DRd** \\  & \(n\) = 200 & \(n\) = 72 & \(n\) = 51 \\ \hline Sex, \(n\) (\%) & & & \\ Male & 99 (49.5) & 41 (56.9) & 30 (58.8) \\ Female & 101 (50.5) & 31 (43.1) & 21 (41.2) \\ Age, median (range), years & 77 (51–91) & 76 (52–92) & 74 (52–94) \\ CCI category, \(n\) (\%) & & & \\ Low (score of 0) & 54 (27.0) & 2 (2.8) & 4 (7.8) \\ Medium (score of 1 or 2) & 92 (46.0) & 36 (50.0) & 18 (35.3) \\ High (score of 3 or 4) & 37 (18.5) & 23 (31.9) & 21 (41.2) \\ Very high (score of \(\geq\)5) & 17 (8.5) & 11 (15.3) & 8 (15.7) \\ Time from diagnosis to DRd initiation, & 16 (0–354) & 214 (28–1520) & 420 (77–1863) \\ median (range), days & 22.47 \(\pm\) 3.30 & 22.39 \(\pm\) 3.03 & 22.36 \(\pm\) 3.36 \\ BMI, mean \(\pm\) SD, kg/m\({}^{2}\) & 22.47 \(\pm\) 3.30 & 22.39 \(\pm\) 3.03 & 22.36 \(\pm\) 3.36 \\ Comorbidities, \(n\) (\%) & & & \\ Congestive heart failure & 51 (25.5) & 26 (36.1) & 21 (41.2) \\ Renal disease & 41 (20.5) & 24 (33.3) & 12 (23.5) \\ Diabetes & 45 (22.5) & 21 (29.2) & 15 (29.4) \\ Without chronic complications & 37 (18.5) & 16 (22.2) & 11 (21.6) \\ With chronic complications & 8 (4.0) & 5 (6.9) & 4 (7.8) \\ Cerebrovascular disease & 37 (18.5) & 17 (23.6) & 12 (23.5) \\ Liver disease & 30 (15.0) & 14 (19.4) & 10 (19.6) \\ Mild & 29 (14.5) & 14 (19.4) & 10 (19.6) \\ Moderate or severe & 1 (0.5) & 0 & 0 \\ Chronic pulmonary disease & 35 (17.5) & 26 (36.1) & 16 (31.4) \\ Peptic ulcer disease & 30 (15.0) & 26 (36.1) & 27 (52.9) \\ Peripheral vascular disease & 12 (6.0) & 8 (11.1) & 2 (3.9) \\ Rheumatic disease & 7 (3.5) & 5 (6.9) & 3 (5.9) \\ Myocardial infarction & 7 (3.5) & 6 (8.3) & 3 (5.9) \\ Dementia & 2 (1.0) & 1 (1.4) & 2 (3.9) \\ Hemiplegia or paraplegia & 2 (1.0) & 0 & 0 \\ AIDS/HIV infection & 1 (0.5) & 0 & 0 \\ \hline \hline \end{tabular}  
* 1L, first line; 2L, second line; \(\geq\)3L, third line or later; AIDS, autoimmune deficiency syndrome; BMI, body mass index; CCI, Charlson Comorbidity Index; DRd, daratumamab + lenalidomide + dexamethasone; HIV, human immunodeficiency virus; SD, standard deviation. Patients who met the exclusion criteria between the time of their multiple myeloma diagnosis and the first administration of DRd were excluded.  
\end{table}
Table 2: Patient baseline characteristics at the first daratumamab + lenalidomide + dexamethasone administration, stratified by line of treatment (\(N\) = 323).